Morgan Stanley analyst Mark Purcell reiterated an Equalweight rating on GlaxoSmithKline (NYSE: GSK) ahead of June 23rd when ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE